Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigerian Women With Breast Cancer (ARETTA)

Trial Profile

Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigerian Women With Breast Cancer (ARETTA)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Cyclophosphamide; Epirubicin; Fluorouracil; Gonadotropin releasing hormone; Letrozole; Pertuzumab; Tamoxifen; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms ARETTA
  • Most Recent Events

    • 08 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Nov 2017.
    • 02 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top